The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome.
The polycystic ovary syndrome (PCOS), a prevalent endocrinopathy of women, has been associated with a clustering of adverse metabolic features, which co-exist with reproductive dysfunction. Lipid abnormalities are very common in lean as well as obese women with PCOS and should be cautiously considered in the therapeutic management of the syndrome. Clinicians should also critically assess the lipidemic effect of pharmaceutical intervention, primarily aimed at hyperandrogenism, anovulation or insulin resistance. Because dyslipidemia may contribute to long-term cardiometabolic and reproductive sequelae in PCOS, it should be considered as an additional therapeutic target when these patients are assigned to appropriate pharmaceutical treatment.
Diamanti-Kandarakis
E
E
Division of Endocrinology, First Department of Medicine, Laiko Hospital, Medical School, University of Athens, Athens, Greece. akandara@otenet.gr
Kandaraki
E
E
Christakou
C
C
Panidis
D
D
D000726:Androgen Antagonists / Q000627:therapeutic use; D003276:Contraceptives, Oral / Q000627:therapeutic use; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D005260:Female; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D017588:Hyperandrogenism / Q000150:complications / Q000188:drug therapy / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D007247:Infertility, Female / Q000188:drug therapy / Q000209:etiology / Q000378:metabolism; D007333:Insulin Resistance; D050356:Lipid Metabolism / Q000187:drug effects*; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism*; D012307:Risk Factors
D000726:Androgen Antagonists; D003276:Contraceptives, Oral; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents